Magnitude Biosciences raised £1.3 million to expand its VivoScan drug screening platform, commercial activity, equipment and team.
- Amount
- $1.8M
- Announced
- 15 September 2026
- Lead
- Northstar Ventures
- Other investors
- North East Spinout Inspire Fund, North East Innovation Fund, Northstar EIS Growth Fund, NPIF II – Maven Equity Finance, Finance Durham Fund
- Use of funds
- Expand VivoScan, increase commercial activity with global pharmaceutical companies, invest in equipment and automation, and recruit additional staff.
- Checked
- Amount and date matched across 2 press sources